Posted by & filed under Accounting Information Systems, Accounting Principles, Advanced Accounting, All Articles, Auditing, Cost Accounting, Ethical Dilemma, Financial Accounting, Intermediate Accounting, Managerial Accounting, Uncategorized.

According to Bloomberg, Novartis AG is preparing for significant demand for its new gene therapy, a potential blockbuster targeting a disease that kills infants. Now the company is looking at the potential for installment payment plans for a treatment that could command a multimillion-dollar price.

1. At what price does Novartis estimate that the drug Zolgensma could be cost-effective?
2. The treatment is a potential cure for what disease?
3. If Zolgensma is an alternative to Biogen Inc.’s drug Spinraza, what is the benefit of having two drugs for the same condition?

Paton, J. (2019). Novartis Sees High Demand for Possible Multimillion-Dollar Drug. Bloomberg, Jan. 31 (Retrievable online at